372 results about "D-Glucopyranose" patented technology

Steviol glycoside isomers are provided having the formula:wherein R1 may be hydrogen, 1-β-D-glucopyranosyl, or 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, and R2 may be hydrogen, 1-β-D-glucopyranosyl, 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2,3-bis(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, or 2-(1-β-D-xylopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl. Methods for making steviol glycoside isomers are also disclosed. These compounds may be present in food and beverage products as non-nutritive sweeteners.

The present invention relates to a process for making a bread product. The process includes the addition of a non-maltogenic exoamylase that hydrolyses starch to a starch medium, and the application of heat to the starch medium. The non-maltogenic exomylase cleaves one or more linear malto-oligosaccharides, predominantly consisting of from four to eight D-glucopyranosyl units, from non-reducing ends of amylopectin side chains. The non-maltogenic exoamylase has an endoamylase activity of less than 0.5 endoamylase units (EAU) per unit of exoamylase activity.

A propiophenone derivative of the formula (I): wherein OX is a hydroxy group which may optionally be protected, Y is a lower alkyl group, and Z is a beta -D-glucopyranosyl group wherein one or more hydroxy groups may optionally be protected, or a pharmaceutically acceptable salt thereof. Said compounds have excellent hypoglycemic activity so that they are useful in the prophylaxis or treatment of diabetes.

The invention relates to crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

A novel glucopyranoside, 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H) benzofuran-7-C-beta-D-glucopyranoside of the formula 1isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a pharmaceutical composition containing 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H)benzofuran-7-C-beta-D-glucopyranoside and to method for the treatment of diabetes using said compound.

The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and / or by its infra-red spectrum.

The invention relates to a crystalline form of 4-(β-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

The invention belongs to the technical fields of organic chemistry and pharmaceutical chemistry, and specifically relates to a preparation method of a 2-deoxy-beta-D-glucopyranosyl triazole compound. According to the invention, a 1,2-deoxy-7-C-acetyl-alpha-D-glucopyranose derivative is subject to a reaction with sodium azide, such that 2-deoxy-beta-D-glucopyranosyl nitrine is produced. Terminal alkyne and a catalyst copper iodide are added to the same reactor, and the 2-deoxy-beta-D-glucopyranosyl triazole compound is produced through a reaction. According to the invention, a one-pot method is adopted, and the method has advantages of mild reaction condition, simple reaction operation, green and environment-protective solvent, and high yield.

The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable by this method, to a pharmaceutical composition and to the use thereof for preparing medicaments.

A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and / or by its infra-red spectrum.

Multiple strains and species of Campylobacter were found to share a common glycan moitie which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1,4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.

The objetive of the present invention was to enhance the skin whitening effects and blackening prevention effects and supply safe and stable topical agents for dermatological use. For that purpose 4-Hydroxyphenyl-alpha-D-glucopyranoside was combined with auxiliary agents such as ascorbic acid and its derivatives, crude drugs and its extracts, hydroxycarboxylic acid and its salts, oil soluble glycyrrhiza extract, gentian extract, phenol derivatives and their salts, placenta extract, kojic acid and its derivative, glucosamine and its derivatives, azelaic acid and its derivatives, retinol and its derivatives, pyridoxin and its derivatives, tocopherol and its derivatives, chitosan and its decomposition products, caffeic acid derivatives, hydroxycinnamate and its derivatives, Umbelliferae plant extracts, mycelial cultures and their extracts, plant leaves and their extracts.

The invention relates to a gastrodin synthesizing method, which can effectively solve the preparation problem of gastrodin to meet the requirements of the gastrodin in pharmaceuticals. The method comprises the steps of adding catalyst perchloric acid, acetylating anhydrous dextrose by using acetic anhydride to produce per-acetyl dextrose, feeding hydrogen bromide to bromizing hemiacetal hydroxyl of the per-acetyl dextrose to produce bromo-tetraacethyl glucose, further and dropwise adding a bromo-tetraacethyl glucose solution into chloroform and tetrabutyl ammonium bromide, carbonate and para hydroxybenzene in water to obtain 4-formyl benzene-2', 3', 4', 6'- tetraacetyl-beta-D-glucopyranose, performing re-crystallization with ethanol, adding raney nickel or palladium and carbon, feeding hydrogen and pressurizing to hydrogenate, performing filtering, adding sodium alcoholate or ammonia in to filtrate to perform protecting group removal until the reaction is finished completely, performing pressure reduction and concentration to obtain crude gastrodin, and re-crystallizing the crude gastrodin by using alcohol or an alcohol and ester solvent or an alcohol and ketone solvent to obtain the gastrodin. The gastrodin synthesizing method is abundant and cheap in raw materials, simple in process, recycled in solvent, small in pollution and high in quality.

The invention relates to a crystalline form of 4-(β-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.

There is provided a heteroaryl 5-thio-β-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient.

Disclosed herein are an anti-biofilm composition and a method to inhibit or prevent cell adhesion and / or biofilm formation by a microorganism, in which use of 1,2,3,4,6-penta-O-galloyl-D-glucopyranose (PGG) is involved therein.

The invention belongs to the technical field of microbes, and in particular relates to an antimicrobial compound and a fermenting preparation method and application thereof. The molecular weight of the antimicrobial compound of the invention is 445, the molecular formula of the antimicrobial compound is C16H23N5O10, the chemical name of the antimicrobial compound is 1-uracil-4-sarkosyl-serylamido-1,4-dideoxy-beta-D-glucopyranosyl acid, and the antimicrobial compound belongs to uracil hexose dipeptide and is named xin'aomycin. The preparation method adopts actinomycetes Streptomyces noursei and genetically improved strains thereof, and comprises the following steps: culturing in a primary liquid culture medium as a seed liquid; inoculating the cultured seed liquid to a secondary liquid culture medium B for culturing, and carrying out fed-batch fermentation culture of fed-batch liquid C; and after fermentation is finished, separating and purifying the structural compound from the fermentation culture liquid. The antimicrobial compound is used for manufacturing pesticide or medicine products. The invention has the characteristics of high yield, simple process and easy industrialization.

The present invention provides an absorbent wound dressing assembly that can be used to stanch, seal, or stabilize a site of tissue injury, tissue trauma, or tissue access. The wound dressing assembly is flexible so that it can be adapted and used to fit in narrow and small wound sites. Generally the wound dressing assembly comprises a flexible carrier material that is impregnated with a non-mammalian material for control of severe bleeding. The preferred non-mammalian material is poly [β-(1→4)-2-amino-2-deoxy-D-glucopyranose] more commonly referred to as chitosan.

The invention discloses a method for chemically synthesizing natural product salidroside. In the method, lewis acid serving as a catalyst, tyrosol of acyl protected phenolic hydroxyl serving as a glycosylation receptor, and beta-D-5 acetyl glucose serving as glycosylation donor perform a glycosylation reaction to obtain 1-[2-(4-acyloxy phenyl) ethyl]-2,3,4,6-O-tetraacetyl-beta-D-glucopyranoside; and acyl protecting group is removed in an alkaline condition to obtain salidroside. Compared with the traditional method, the method has easily available raw materials, the glycosylation receptor, the glycosylation product and the final product can be prepared through recrystallization, column chromatography and other purification processes are eliminated, the reaction step is short, the preparation process is simple, the glycosylation reaction catalyst has low cost and is easily available, so that the preparation cost is remarkably reduced; and a heavy metal salt catalyst is not used in the reaction, so that the synthesis product is more suitable to be used as a raw material of medicaments and health-care products. The method is suitable for industrial production of salidroside.

Steviol glycoside isomers are provided having the formula:wherein R1 may be hydrogen, 1-β-D-glucopyranosyl, or 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, and R2 may be hydrogen, 1-β-D-glucopyranosyl, 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2,3-bis(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, or 2-(1-β-D-xylopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl. Methods for making steviol glycoside isomers are also disclosed. These compounds may be present in food and beverage products as non-nutritive sweeteners.

The invention provides a method for detecting an active ingredient (3R) -3-methyl-7-hydroxymethyl-8-hydroxyl-3,4-dihydroisocoumarin-6-O-beta-D-glucopyranoside, namely KFX-4 in an American cockroach extract. In the method, high performance liquid chromatography (HPLC) is adopted, octadecylsilane chemically bonded silica is taken as a filler; methanol or acetonitrile-water (0-50:100-50 V / V) is taken as a mobile phase of which the flow speed is between 0.2 and 2.0 ml / min; the detection wavelength is one or more wavelengths of between 210 and 400 nanometers; a diode array detector is adopted; the sample size is between 5 and 50 mu l; theoretical plate number is not less than 4,000 when calculated according to a KFX-4 peak; the separation degree with a neighboring impurity peak is more than 1.5; chromatographic analysis is performed; and KFX-4 content is calculated by a peak area external standard method. An effective quality control method is provided for Chinese medicinal Kangfuxin solution and the method has a large practical value in the aspect of improving product quality and medicament safety.

The invention discloses base fluid for diluting semens of equus animals and a preparation method and a use method thereof. The base fluid contains A fluid and skimmed milk. The A fluid contains glucose, raffinose, D-glucopyranose, trisodium citrate, ppotassium citrate and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). The preparation method for the base fluid includes weighing various components of the A fluid into a sterile beaker, adding double-distilled water, dissolving, bringing to volume, filtering, split charging, sterilizing, and sealing to obtain the A fluid, and adding same amount of the skimmed milk into the A fluid to be evenly mixed. Users can also add penicillin and dihydrostreptomycin to the base fluid or add penicillin, dihydrostreptomycin, yolk and glycerol into the base fluid. The base fluid is suitable for semen dilution and normal temperature preservation, low temperature preservation and freezing preservation of the semens of the equus animals. The base fluid for diluting semens of equus animals and the preparation method and the use method of the base fluid have the advantages of being simple to prepare, convenient to use, good in preservation effect of the semens of the equus animals, multi-purpose, time-saving, labor-saving and applicable to mass production and application.

The invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.

The invention discloses an abelmoschus manihot polysaccharide with an anti-tumor activity and a preparation method thereof. The polysaccharide is formed by beta-D-glucopyranose, alpha-D-mannopyranose, alpha-D-galactose and alpha-L-fucopyranose in a mol ratio of 1: 0.91: 2.14: 1.0, and has the molecular weight of 8867. The structural formula of a basic unit of the polysaccharide is that alpha-D-galactose (1->6) and alpha-D-mannopyranose (2->6) are taken as main chains and mannose C-3 branches are connected with the alpha-L-fucopyranose (1->3) and connected with the beta-D-glucopyranose (->1). According to the abelmoschus manihot polysaccharide disclosed by the invention, an extraction and separation process is selected through a large number of experiments; firstly, a water extraction and alcohol precipitation method is used for obtaining a rough polysaccharide and then protein is removed; and then, a DEAE-52 (Diethyl Aminoethanol-52) cellulose resin and SephadexG-100 gel resin are combined for purifying to prepare the abelmoschus manihot polysaccharide with high purity. Anti-tumor experiment results show that the abelmoschus manihot polysaccharide has very good anti-tumor activity and has no untoward effects after being used for a long period; and the abelmoschus manihot polysaccharide can be conveniently prepared into medicines with various preparations with pharmaceutically acceptable carriers, and is convenient to take clinically.